Eric Bjerkholt - 15 Mar 2026 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Judit Ryvkin, Attorney-in-Fact
Issuer symbol
MIRM
Transactions as of
15 Mar 2026
Net transactions value
-$670,243
Form type
4
Filing time
17 Mar 2026, 19:30:20 UTC
Previous filing
30 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
BJERKHOLT ERIC CHIEF FINANCIAL OFFICER C/O MIRUM PHARMACEUTICALS, INC., 989 E HILLSDALE BLVD., SUITE 300, FOSTER CITY /s/ Judit Ryvkin, Attorney-in-Fact 17 Mar 2026 0001197350

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MIRM Common Stock Options Exercise +13,334 +30% 57,075 15 Mar 2026 Direct F1
transaction MIRM Common Stock Sale $670,243 -7,287 -13% $91.98 49,788 16 Mar 2026 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MIRM Performance Restricted Stock Units Options Exercise -13,334 -67% $0.000000* 6,666 15 Mar 2026 Common Stock 13,334 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2 Shares sold to cover tax withholding obligations associated with the vesting of the performance restricted stock units.
F3 The shares vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027.